Page last updated: 2024-09-05

sorafenib and Adenocarcinoma, Alveolar

sorafenib has been researched along with Adenocarcinoma, Alveolar in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, FY; Chao, TT; Chen, KF; Chen, PT; Chen, YL; Shiau, CW; Su, WP; Tai, WT; Wang, CY; Weng, CY; Yu, CJ; Yuan, A	1
Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ	1
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G	1
Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S	1
Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA	1

Trials

3 trial(s) available for sorafenib and Adenocarcinoma, Alveolar

Article	Year
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome	2011
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clinical lung cancer, 2011, Volume: 12, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome	2011
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate	2012

Other Studies

2 other study(ies) available for sorafenib and Adenocarcinoma, Alveolar

Article	Year
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome	2010

Article

Year

Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5

Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome

2010